@jq1234t @BertrandBio I stand corrected 👍 and it probably also means i made a fuss about nothing and we can just see it as an additional trial, sry on your point; Pre-treatment with Daratumumab was found to enhance the efficacy of Teclistamab preclinically
RT @TrueDiagnostics: Preclinical Activity of JNJ-7957, a Novel BCMAxCD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Poten…
Preclinical Activity of JNJ-7957, a Novel BCMAxCD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab https://t.co/7BaC9L3PwW
RT @PLMcCarthyMD: Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentia…
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab https://t.co/e5apPBFRVU
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab https://t.co/ttbFVUYK9V
RT @BertrandBio: Interesting perspectives on combos & population selection with this $GMAB $JNJ BCMAxCD3 duobody (in vitro data) Preclinic…
RT @BertrandBio: Interesting perspectives on combos & population selection with this $GMAB $JNJ BCMAxCD3 duobody (in vitro data) Preclinic…
Interesting perspectives on combos & population selection with this $GMAB $JNJ BCMAxCD3 duobody (in vitro data) Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab
New article: Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab. https://t.co/jCC8PFqhQX #MMSM #MultipleMyeloma #hematology
RT @EgidiusLambrech: Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is poten…
Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by #daratumumab JNJ-957 was created under collaboration between @Genmab and Janssen using Genmab's #DuoBody technology $GMAB $JNJ
Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab https://t.co/MzQqkPqjCJ